Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

23 Sept 2021

Abstract excerpt

Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and predisposition to acute myeloid leukemia (AML). Stem cell genomic instability, microenvironmental aberrations, and somatic mutations contribute to leukemic transformation. The hypomethylating agents (HMAs), azacitidine and decitabine are the standard of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34638574
DOI: 10.3390/ijms221910232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromePMID 34638574Read ↗

Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the diseaseSemantic proximity Read ↗

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapySemantic proximity Read ↗

Current and emerging strategies for management of myelodysplastic syndromes.Semantic proximity Read ↗

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.Semantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.Semantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Established and emerging targeted therapies in the myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.